DrugPatentWatch Database Preview
MYOVIEW 30ML Drug Profile
» See Plans and Pricing
When do Myoview 30ml patents expire, and what generic alternatives are available?
Myoview 30ml is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.
This drug has eight patent family members in seven countries.
The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.
DrugPatentWatch® Generic Entry Outlook for Myoview 30ml
Myoview 30ml was eligible for patent challenges on February 9, 2000.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 10, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for MYOVIEW 30ML
| International Patents: | 8 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MYOVIEW 30ML at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for MYOVIEW 30ML
Generic Entry Date for MYOVIEW 30ML*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MYOVIEW 30ML
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Astellas Pharma Inc | Phase 2 |
| GE Healthcare | Phase 4 |
US Patents and Regulatory Information for MYOVIEW 30ML
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | MYOVIEW 30ML | technetium tc-99m tetrofosmin kit | INJECTABLE;INJECTION | 020372-002 | Jul 7, 2005 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MYOVIEW 30ML
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2010539222 | Start Trial |
| Spain | 2562441 | Start Trial |
| Japan | 2764037 | Start Trial |
| China | 1024013 | Start Trial |
| United Kingdom | 8808414 | Start Trial |
| Japan | 5764328 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for MYOVIEW 30ML
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 300736 | Netherlands | Start Trial | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
